OverviewChartNewsTraderScreen

ObsEva SA/  CH1260041939  /

Cboe Europe CXE
3/8/2024  5:02:03 PM Chg. - Volume Bid10:04:48 AM Ask5:19:05 PM High Low
0.018CHF - 1,869
Turnover: 40.466		 -Bid Size: - -Ask Size: - 0.025 0.018
GlobeNewswire 4/3 ObsEva Announces Delisting from SIX Swiss Exchange and Exemption from Certain Obligations Associated...
GlobeNewswire 3/19 ObsEva Announces Update on Board of Directors
GlobeNewswire 3/8 XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming ...
GlobeNewswire 2/28 ObsEva Announces Wind-Down of Operations and Notifies SIX that it Will Lack the Resources to Establi...
GlobeNewswire 1/31 Geneva Court Grants Temporary Moratorium to ObsEva
GlobeNewswire 11/30/2023 ObsEva Announces Application for a Moratorium to Facilitate Pivotal Deals
GlobeNewswire 11/7/2023 XOMA Reports Third Quarter 2023 Financial Results and Highlights Upcoming Events Expected to Drive S...
GlobeNewswire 10/27/2023 Organon Returns Ebopiprant to XOMA
GlobeNewswire 9/27/2023 ObsEva Files half Year 2023 Financial Statements
GlobeNewswire 3/22/2022 ObsEva Announces Additional Efficacy Results for Linzagolix 200 mg with Add-Back Therapy (ABT) and L...
GlobeNewswire 3/22/2022 ObsEva Announces Additional Efficacy Results for Linzagolix 200 mg with Add-Back Therapy (ABT) and L...
GlobeNewswire 3/10/2022 ObsEva Announces Year End 2021 Financial Results and Provides Corporate Update
GlobeNewswire 2/10/2022 ObsEva Enters into Licensing Agreement with Theramex for the Commercialization of Linzagolix
GlobeNewswire 2/4/2022 ObsEva Provides Update on EU Marketing Authorisation Process for Linzagolix, an Oral GnRH Antagonist...
GlobeNewswire 2/1/2022 ObsEva Appoints Katja Buhrer as Chief Strategy Officer
GlobeNewswire 1/28/2022 ObsEva Announces Corporate Updates
GlobeNewswire 1/6/2022 ObsEva Announces Positive Topline Results for Linzagolix 200 mg with Add-Back Therapy in the Phase 3...
GlobeNewswire 1/5/2022 Aspira Women’s Health Announces Fourth Quarter Operational Metrics and Provides Updates on Its OvaWa...
GlobeNewswire 1/3/2022 ObsEva to Present at the H.C. Wainwright BioConnect 2022 Conference
GlobeNewswire 12/17/2021 ObsEva Announces Positive CHMP Opinion for Linzagolix, an Oral GnRH Antagonist, for the Treatment of...
GlobeNewswire 12/13/2021 ObsEva Appoints Will Brown as Chief Financial Officer
GlobeNewswire 12/11/2021 Annual Changes to the Nasdaq Biotechnology Index
GlobeNewswire 12/10/2021 ObsEva Hosts Symposium and Presents Clinical Data on Oral GnRH Antagonist Linzagolix at SEUD Congres...
GlobeNewswire 12/2/2021 ObsEva Announces Symposium and Presentation of Clinical Data on Oral GnRH Antagonist Linzagolix at S...
GlobeNewswire 11/29/2021 Rapid7 Appoints Tim Adams as Chief Financial Officer